**3.3 RDP with CI-DME**

Anti-VEGF is considered first- line treatment in CI-DME. RBZ and AFB were highly effective in treating PDR [15, 16].

	- If DME does not require further anti-VEGF, NV status should be re-evaluated.
	- If NV worsens significantly, it is suggested to decide on therapy according to Section 3.1 B (PDR without DME).
	- In case of new DME activity, it is suggested to reactivate anti-VEGF therapy.

Advantages and disadvantages of treatment options should be considered, as well as the individual conditions of the patient.

*Treatment Algorithm in Proliferative Diabetic Retinopathy - From Protocols to the Real World DOI: http://dx.doi.org/10.5772/intechopen.99843*
